The scientist’s investigation covers issues in Internal medicine, Diabetes mellitus, Endocrinology, Type 2 diabetes and Insulin. His Diabetes mellitus study combines topics from a wide range of disciplines, such as Disease and Pneumonia. His studies deal with areas such as Allele, Genotype and Urology as well as Endocrinology.
His Type 2 diabetes research incorporates themes from Hypoglycemia, Obesity, Surgery, MEDLINE and Intensive care medicine. Stefano Del Prato focuses mostly in the field of Insulin, narrowing it down to topics relating to Carbohydrate metabolism and, in certain cases, Lipotoxicity. His Impaired glucose tolerance study, which is part of a larger body of work in Insulin resistance, is frequently linked to Serum triglycerides, bridging the gap between disciplines.
His primary areas of investigation include Internal medicine, Diabetes mellitus, Endocrinology, Type 2 diabetes and Insulin. Stefano Del Prato studies Internal medicine, namely Insulin resistance. His research integrates issues of Obesity, Surgery, MEDLINE and Intensive care medicine in his study of Diabetes mellitus.
His work is connected to Metabolic syndrome, Pancreatic islets, Carbohydrate metabolism, Albuminuria and Islet, as a part of Endocrinology. His Type 2 diabetes study integrates concerns from other disciplines, such as Metformin, Randomized controlled trial, Glycemic and Disease. Insulin is represented through his Basal, Insulin oscillation and Postprandial research.
Stefano Del Prato mainly focuses on Internal medicine, Type 2 diabetes, Diabetes mellitus, Metformin and Intensive care medicine. His studies in Internal medicine integrate themes in fields like Gastroenterology, Placebo and Type 1 diabetes. His biological study spans a wide range of topics, including Randomized controlled trial, Glycemic, Combination therapy and Glucagon-like peptide 1 receptor.
His research integrates issues of Obesity, Insulin, MEDLINE and Renal function in his study of Diabetes mellitus. His Metformin study necessitates a more in-depth grasp of Endocrinology. Stefano Del Prato mostly deals with Body mass index in his studies of Endocrinology.
His primary areas of study are Diabetes mellitus, Internal medicine, Type 2 diabetes, Placebo and Hazard ratio. The various areas that Stefano Del Prato examines in his Diabetes mellitus study include Severity of illness, Obesity, Increased risk and Pneumonia. His Internal medicine research includes elements of Gastroenterology and Type 2 Diabetes Mellitus.
His Type 2 diabetes research includes themes of Metformin, Intensive care medicine and Urology. His Metformin study is related to the wider topic of Endocrinology. His Endocrinology study combines topics from a wide range of disciplines, such as Cognition and Sensory processing, Sensory system.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Steven E Kahn;Mark E Cooper;Stefano Del Prato.
The Lancet (2014)
How Do We Define Cure of Diabetes
John B. Buse;Sonia Caprio;William T. Cefalu;Antonio Ceriello.
Diabetes Care (2009)
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes
Valeriya Lyssenko;Roberto Lupi;Piero Marchetti;Silvia Del Guerra.
Journal of Clinical Investigation (2007)
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations.
Francesco Rubino;David M Nathan;Robert H Eckel;Philip R Schauer.
Obesity Surgery (2017)
Prolonged Exposure to Free Fatty Acids Has Cytostatic and Pro-Apoptotic Effects on Human Pancreatic Islets: Evidence that β-Cell Death Is Caspase Mediated, Partially Dependent on Ceramide Pathway, and Bcl-2 Regulated
Roberto Lupi;Francesco Dotta;Lorella Marselli;Silvia Del Guerra.
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
Francesco Rubino;David M. Nathan;Robert H. Eckel;Philip R. Schauer.
Diabetes Care (2016)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F Hernandez;Jennifer B Green;Salim Janmohamed;Ralph B D'Agostino.
The Lancet (2018)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck;Stefano Del Prato;Juris J. Meier;Santiago Durán-García.
Diabetes Care (2011)
Management of type 2 diabetes: new and future developments in treatment.
Abd A Tahrani;Abd A Tahrani;Clifford J Bailey;Stefano Del Prato;Anthony H Barnett;Anthony H Barnett.
The Lancet (2011)
Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients
Francesco Dotta;Stefano Censini;Astrid G. S. van Halteren;Lorella Marselli.
Proceedings of the National Academy of Sciences of the United States of America (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: